 | |
| Clinical data | |
|---|---|
| Other names | A-93431; ABT-431; ABT431; DAS-431; DAS431 |
| Routes of administration | Parenteral (e.g.,intravenous,inhalation)[1] |
| Drug class | DopamineD1-like receptoragonist |
| ATC code |
|
| Pharmacokinetic data | |
| Bioavailability | Oral: ≤4%[1] Sublingual: 10–13%[1] Inhalational: 82–107%[1] |
| Metabolism | Deacetylation[1] |
| Metabolites | A-86929[1] |
| Eliminationhalf-life | 3–4 hours[1] |
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C22H25NO4S |
| Molar mass | 399.51 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Adrogolide (INNTooltip International Nonproprietary Name; developmental code namesA-93431,ABT-431, andDAS-431), also known asadrogolide hydrochloride (USANTooltip United States Adopted Name) in the case of thehydrochloridesalt, is adopamineD1-like receptoragonist which was under development for the treatment ofParkinson's disease,cognition disorders, andcocaine-related disorders but was never marketed.[2][3][4][1][5]
It is achemically stable and rapidlyconverteddiacetateesterprodrug of the highlyselective dopamineD1 andD5 receptorfull agonistA-86929.[1] The effects of adrogolide and A-86929 in animals and humans have been studied.[1][5]Side effects of adrogolide in humans includedinjection site reactions,asthenia,headache,nausea,vomiting,postural hypotension,vasodilation, anddizziness.[1]
Adrogolide was under development byAbbott Laboratories and DrugAbuse Sciences.[2][3][4] It reachedphase 2clinical trials for Parkinson's disease prior to the discontinuation of its development in 2001.[2][3][4] The drug is said to have been the first extensively characterized dopamine D1 receptor full agonist.[1]
ABT-431. Adrogolide Hydrochloride [...]
 | Thisdrug article relating to thenervous system is astub. You can help Wikipedia byadding missing information. |